Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this vaccine maker have returned +7.6%, compared to the Zacks S&P 500 composite's +3.8% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Novavax falls in, has gained 3.8%. The key question now is: What could be the stock's future dire ...

文章核心观点 - 华尔街分析师的股票评级建议对投资者的投资决策影响很大,但其可靠性存在问题 [1][2] - 分析师的评级存在正偏差,往往给出过于乐观的评级,不能真实反映股票的未来走势 [6][11] - 相比于分析师评级,使用Zacks Rank等量化模型更能准确预测股票的短期价格走势 [8][12][13] 公司分析 - Novavax目前的平均券商评级(ABR)为2.00,表示"买入"评级 [3] - 6家券商中有3家给出"强烈买入"评级,占50% [4] - 尽管ABR显示买入,但仅依此做出投资决策可能不太合适 [5] - Novavax最近1个月内,当前年度的盈利预测已上调33.5% [15] - 分析师对Novavax盈利前景的乐观预期,可能是该股短期内上涨的合理原因 [16][17] 行业分析 - 券商分析师的评级存在正偏差,他们给出的"强烈买入"评级远多于"强烈卖出" [6][11] - 这表明券商的利益与散户投资者的利益并不完全一致,无法真正指引股票未来走势 [7] - 相比于分析师评级,使用Zacks Rank等量化模型更能准确预测股票的短期价格走势 [8][12][13] - Zacks Rank和分析师评级(ABR)是两种完全不同的指标 [9][10][14]

Novavax (NVAX) ended the recent trading session at $12.06, demonstrating a +1.34% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.1%. At the same time, the Dow lost 0.08%, and the tech-heavy Nasdaq gained 0.28%.Coming into today, shares of the vaccine maker had lost 34.51% in the past month. In that same time, the Medical sector lost 0.44%, while the S&P 500 gained 4.08%.Investors will be eagerly watching for the performance of Novavax in ...

Nvidia (NASDAQ:NVDA) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which sparked an AI tsunami. Yet there is a world of stocks that are outperforming Nvidia. While the technology sector provides opportunity with companies like Super Micro Computer (NASDAQ:SMCI) far outstripping the chipmaker’s gains, investors should widen their lens even further. Below are three fast-growing stocks that a ...

We will know a lot more about the vaccine maker's long-term prospects in 12 months. What a difference a few months make. Vaccine specialist Novavax (NVAX -1.32%) started the year poorly, continuing with the issues it has encountered since mid-2021. Those headwinds included the difficulties it faced in launching its COVID vaccine in the U.S. and the significant slowdown in demand for these products, leading to a decline in revenue and earnings for the biotech. However, several developments have jolted Novava ...

The latest trading session saw Novavax (NVAX) ending at $12.66, denoting a -1.33% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.41%. At the same time, the Dow lost 0.12%, and the tech-heavy Nasdaq lost 0.71%. The the stock of vaccine maker has fallen by 15.87% in the past month, lagging the Medical sector's gain of 1.74% and the S&P 500's gain of 3.53%. Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upco ...

Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ:NVAX) the green light to target a specific Covid-19 variant. Yet, it’s too late to buy Novavax stock with confidence as meme-stock madness sent the share price to the moon already. I’ll bet you never imagined that there would be a connection between GameStop (NYSE:GME) and Novavax. Yet, in these bizarre times, there’s actually a link between ...

文章核心观点 - 诺华公司(NVAX)向欧洲药品管理局(EMA)提交了更新其蛋白质疫苗以针对2024/2025年疫苗接种季的监管申请 [1][2][3] - 该更新疫苗针对JN.1变异株进行了调整,但NVAX声称该疫苗对当前流行的KP.2和KP.3变异株也有效 [2] - 这一提交符合EMA于4月30日发布的指导意见,建议Moderna、诺华和辉瑞等COVID-19疫苗制造商更新疫苗以针对JN.1变异株 [3] - 诺华正在与全球其他监管机构合作,以获得更新其蛋白质疫苗的授权/批准 [4] - 与此同时,诺华的疫苗在欧盟仅获批用于12岁及以上人群,公司也向FDA提交了类似的申请,寻求更新疫苗以应对即将到来的秋季 [5][6][7] 行业概况 - 与辉瑞和Moderna相比,诺华由于其疫苗上市延迟,未能在去年的疫苗接种季从中获益 [9] - 诺华希望能够尽早参与即将到来的疫苗接种季,以抓住这一机会 [9] - 从明年开始,赛诺菲将获得共同推广诺华蛋白质疫苗的权利,并有权开发和销售与其流感疫苗的组合疫苗 [10] - 这笔交易为诺华注入了新的生机,帮助其解决了"持续经营"的担忧 [11][12] - 利用赛诺菲交易的资金,诺华开始计划扩大其管线,包括开发针对H5N1禽流感的新疫苗方法 [12]

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this vaccine maker have returned -9.7% over the past month versus the Zacks S&P 500 composite's +2.7% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax belongs, has lost 0.5% over this period. Now the key question is: Where could the stock be headed in the near te ...

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md., June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidan ...